Cellectar Biosciences' Cash and Cash Equivalents, As of March 31, 2024, Was $40M That Is Expected To Provide Cash Runway Into Fourth Quarter Of 2024
Cellectar Biosciences' Cash and Cash Equivalents, As of March 31, 2024, Was $40M That Is Expected To Provide Cash Runway Into Fourth Quarter Of 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.